Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Apotex Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (1354)
Cancellation or suspension (47)
Prescription medicine registration (18)
Australian public assessment report (AusPar) (1)
Listed medicine compliance report (1)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2024 (4)
2023 (16)
2022 (159)
2021 (104)
2020 (216)
2019 (124)
2018 (380)
2017 (302)
2016 (34)
2015 (52)
2014 (32)

Search

Sponsor content

1423 result(s) found, displaying 671 to 680

APOTEX-OLANZAPINE olanzapine 10 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
APOTEX-OLANZAPINE olanzapine 15 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
APOTEX-OLANZAPINE olanzapine 20 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
APOTEX-OLANZAPINE olanzapine 2.5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
DASATINIB APOTEX, APO-DASATINIB (Apotex Pty Ltd)

25 July 2018

Prescription medicine registration

Active ingredients: Dasatinib.
APO-Entecavir entecavir (as monohydrate) 0.5mg tablet blister pack Section 30(1)(c) of the Act

11 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
APO-Entecavir entecavir (as monohydrate) 1mg tablet blister pack Section 30(1)(c) of the Act

11 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
PHARMACY CARE AMOROLFINE ANTI FUNGAL NAIL TREATMENT amorolfine 5% w/v (as hydrochloride) nail lacquer application bottle Cancelled under Section 30(1)(c) of the Act

29 June 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GENRX CANDESARTAN candesartan cilexetil 4 mg tablet blister Cancelled under Section 30(1)(c) of the Act

25 June 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GENRX CANDESARTAN candesartan cilexetil 8 mg tablet blister Cancelled under Section 30(1)(c) of the Act

25 June 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd

Pages

First page
Previous page
…
Page 64
Page 65
Page 66
Page 67
Current page 68
Page 69
Page 70
Page 71
Page 72
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.